This is a federal contract award from the Department of Veterans Affairs (VA) to Caredx, Inc., a for-profit medical testing company based in Brisbane, California. The contract is for $4,807,230.45 and covers the delivery of lab tests for post-transplant organ rejection, primarily the AlloMap and AlloSure genetic testing kits used to assess organ rejection risks in transplant patients.
The contract is not a set-aside and has an ultimate completion date of March 31, 2026. It is a delivery order contract, with a firm fixed price pricing type. Caredx has been awarded multiple Indefinite Delivery Vehicle (IDV) contracts with the VA to provide these specialized transplant diagnostic services across different VA healthcare networks. The company also holds smaller contracts with other federal agencies like the NIH and CDC for next-generation sequencing reagents and molecular testing products.
Generated 3/29/25, 10:00 AM